X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
VE303 is a defined bacterial consortium therapeutic candidate designed for the prevention of recurrent Clostridioides difficile infection (rCDI). It was granted orphan drug designation and fast track designation.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 08, 2023
Details:
The financing will be used to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AXA IM Alts
Deal Size: $106.5 million Upfront Cash: Undisclosed
Deal Type: Financing April 25, 2023
Details:
VE303 is an orally administered, rationally-defined bacterial consortium candidate being developed for high-risk Clostridioides difficile (CDI) infection.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 28, 2022
Details:
Data presentations include review of the VE303 Phase 2 CONSORTIUM study, in which VE303 was well tolerated and highly active at preventing Clostridioides difficile infection recurrence in subjects at high risk of recurrence.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 24, 2022
Details:
Vedanta reported positive topline results from Phase 2 CONSORTIUM trial, in which VE303 was associated with a 31.7% absolute risk reduction in rate of recurrence when compared with placebo, representing a greater than 80% reduction in odds of a CDI recurrence.
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: PureTech Health
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 13, 2022
Details:
Proceeds expected to be used primarily to support a Phase 3 trial of Vedanta’s lead candidate VE303 in Clostridioides difficile infection (CDI) and a Phase 2 trial of VE202 in inflammatory bowel disease (IBD).
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: affiliates of Magnetar Capital
Deal Size: $68.0 million Upfront Cash: Undisclosed
Deal Type: Series D Financing July 21, 2021
Details:
The funding will support completion of an ongoing Phase 2 trial and further clinical development of VE303, a rationally-defined, orally-administered live biotherapeutic product (LBP).
Lead Product(s): VE303
Therapeutic Area: Infections and Infectious Diseases Product Name: VE303
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: BARDA
Deal Size: $76.9 million Upfront Cash: $7.4 million
Deal Type: Funding September 30, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
